Patents by Inventor David Gomez-Varela

David Gomez-Varela has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11433323
    Abstract: The present invention relates to a device for separation of plasma or serum from a blood sample from a small blood volume (e.g. capillary blood). The device comprises a separation member, an extraction member and a housing. The extraction member comprises a base and one or more microstructures protruding from and being integrally formed with said base, wherein said one or more microstructures are configured to extract plasma or serum from said separation member by capillary forces. The present invention further provides methods for separating plasma or serum using the device according to the present invention. Similarly, also methods for analyzing one or more proteins and/or metabolites contained in plasma or serum that is separated using a device according to the present invention are provided.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: September 6, 2022
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V
    Inventor: David Gomez Varela
  • Publication number: 20210086106
    Abstract: The present invention relates to a device for separation of plasma or serum from a blood sample from a small blood volume (e.g. capillary blood). The device comprises a separation member, an extraction member and a housing. The extraction member comprises a base and one or more microstructures protruding from and being integrally formed with said base, wherein said one or more microstructures are configured to extract plasma or serum from said separation member by capillary forces. The present invention further provides methods for separating plasma or serum using the device according to the present invention. Similarly, also methods for analyzing one or more proteins and/or metabolites contained in plasma or serum that is separated using a device according to the present invention are provided.
    Type: Application
    Filed: April 30, 2018
    Publication date: March 25, 2021
    Inventor: David Gomez Varela
  • Patent number: 7910100
    Abstract: The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding these anti-EAG1 antibodies, antibody fragments or derivatives and to vectors comprising such nucleic acid molecules. The invention additionally relates to methods for the preparation of such anti-EAG1 antibodies, antibody fragments or derivatives thereof, pharmaceutical compositions comprising these antibodies, antibody fragments or derivatives, and methods of using the antibodies, antibody fragments or derivatives or the compositions for a variety of purposes, such as diagnosing disease, treating disease, assessing for the presence of EAG1-expressing cells, or blocking EAG1 function in cells.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: March 22, 2011
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissen
    Inventors: Walter Stühmer, Hendrik Knötgen, David Gómez-Varela, Luis A. Pardo, Mike Rothe, Esther Zwick-Wallasch, Kerstin Dehne
  • Publication number: 20090028851
    Abstract: The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to methods for the preparation of said antibody, antibody fragments or derivatives thereof and to pharmaceutical compositions comprising the same. Furthermore, the use of said antibody, antibody fragment or derivative thereof and also diagnostic compositions comprising said components are disclosed in the specification. The invention also relates to a method of assessing for the presence of EAG1 expressing cells and for a method of blocking EAG1 function in said cells. The invention further relates to a method of treating diseases with the help or said antibody or antibody fragment or derivative thereof.
    Type: Application
    Filed: October 4, 2005
    Publication date: January 29, 2009
    Applicants: MAXPLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCH, U3 PHARMA AG
    Inventors: Walter Stuhmer, Hendrik Knotgen, David Gomez-Varela, Luis A. Pardo, Mike Rothe, Esther Zwick-Wallasch, Kerstin Dehne